Multicentre Trial Of Carboplatin/Paclitaxel Versus Oxaliplatin/Capecitabine, Each With/Without Bevacizumab, As First Line Chemotherapy For Patients With Mucinous Epithelial Ovarian Cancer (Meoc).

5528 Background: Advanced mEOC responds poorly to standard therapy. It comprises u003c 8% pts in ovarian cancer trials, so it is difficult to examine treatment effects in this subgroup. We conducted the first ever randomised trial specific for this rare subgroup (4 regimens). Methods: mEOC/GOG 241 is a multi-centre randomised phase II trial (UK, USA) in chemo- naive pts with advanced/recurrent disease. Six 21-day cycles of chemotherapy were given to each of 4 arms: (A) carboplatin (AUC 5/6) + paclitaxel (175mg/m2); (B) oxaliplatin (130 mg/m2) + capecitabine (850mg/m2 bd; D1-14); (C) carboplatin/paclitaxel with bevacizumab (15mg/kg); (D) oxaliplatin/capecitabine with bevacizumab. Bevacizumab was given concurrently, then alone 3-weekly for 12 more cycles. 332 pts required to detect 5 month increase in median PFS for oxaliplatin/capecitabine (B+D), or adding bevacizumab (C+D). Results: Trial stopped early (2013) due to poor accrual (median follow up 23 months; 31 progressions/deaths). 50 pts recruited: n = 13, 1...